Synthesis and Pharmacological Evaluation of SNC80 Analogues with a Bridged Piperazine Ring

To discover novel δ‐opioid receptor ligands derived from SNC80 (1), a series of 6,8‐diazabicyclo[3.2.2]nonane derivatives bearing two aromatic moieties was prepared, and the affinity toward δ, μ, and κ receptors, as well as σ receptors, was investigated. After removal of the 4‐methoxybenzyl and 2,4‐...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ChemMedChem 2009-12, Vol.4 (12), p.2111-2122
Hauptverfasser: Holl, Ralph, Jung, Bettina, Schepmann, Dirk, Humpf, Hans-Ulrich, Grünert, Renate, Bednarski, Patrick J., Englberger, Werner, Wünsch, Bernhard
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2122
container_issue 12
container_start_page 2111
container_title ChemMedChem
container_volume 4
creator Holl, Ralph
Jung, Bettina
Schepmann, Dirk
Humpf, Hans-Ulrich
Grünert, Renate
Bednarski, Patrick J.
Englberger, Werner
Wünsch, Bernhard
description To discover novel δ‐opioid receptor ligands derived from SNC80 (1), a series of 6,8‐diazabicyclo[3.2.2]nonane derivatives bearing two aromatic moieties was prepared, and the affinity toward δ, μ, and κ receptors, as well as σ receptors, was investigated. After removal of the 4‐methoxybenzyl and 2,4‐dimethoxybenzyl protecting groups, the pharmacophoric N,N‐diethylcarbamoylbenzyl residue was attached to the 6,8‐diazabicyclo[3.2.2]nonane framework to yield the designed δ receptor ligands. In a first series of compounds the benzhydryl moiety of SNC80 was dissected, and one phenyl ring was attached to the bicyclic framework. In a second series of δ ligands the complete benzhydryl moiety was introduced into the bicyclic scaffold. The determined δ receptor affinities show that compounds based on an (R)‐glutamate‐derived bicyclic scaffold possess higher δ receptor affinity than their (S)‐glutamate‐derived counterparts. Furthermore, an intact benzhydryl moiety leads to δ receptor ligands that are more potent than compounds with two separated aromatic moieties. Compound 24, with the same spatial arrangement of substituents around the benzhydryl stereocenter as SNC80, shows the highest δ receptor affinity of this series: Ki=24 nM. Whereas the highly potent δ ligands reveal good selectivity against μ and κ receptors, the σ1 and/or σ2 affinities of some compounds are almost in the same range as their δ receptor affinities, such as compound 25 (σ2: Ki=83 nM; δ: Ki=75 nM). In [35S]GTPγS assays the most potent δ ligands 24 and 25 showed almost the same intrinsic activity as the full agonist SNC80, proving the agonistic activity of 24 and 25. The enantiomeric 4‐benzylidene derivatives 15 and ent‐15 showed selective cytotoxicity toward the 5637 (bladder) and A‐427 (small‐cell lung) human tumor cell lines. δ‐Opioid receptor agonists with a bridged piperazine scaffold were designed and synthesized. Whereas compounds with phenyl residues attached to different ring positions (compounds at center) did not show high δ affinity, introduction of the intact benzhydryl moiety at N8 (compounds at right) led to a potent δ agonist (Y=H2, Ki=24 nM).
doi_str_mv 10.1002/cmdc.200900358
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733603794</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733603794</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4078-f28f4900c1b27436122e379a88e8d641d33836766aabbe2c86863f3a2488b0ff3</originalsourceid><addsrcrecordid>eNqFkE1PGzEQhi1UVCjttcfKt542-Cv27BG2lCJRoIUKiYs16_Umhv1I7U0h_PouShR662lGmud9NHoJ-cjZhDMmDl1buYlgLGdMTmGH7HPQLDMczJvtbvI98i6le8aUAg5vyR7PQRgGep_cXa-6Ye5TSBS7il7NMbbo-qafBYcNPfmDzRKH0He0r-n1RQGMHnU4npc-0ccwzCnS4xiqmR_DYeEjPofO05-hm70nuzU2yX_YzAPy6-vJTfEtO788PSuOzjOnmIGsFlCr8X3HS2GU1FwIL02OAB4qrXglJUhttEYsSy8caNCyligUQMnqWh6Qz2vvIva_x7cG24bkfNNg5_tlskZKzUajGsnJmnSxTyn62i5iaDGuLGf2pU77Uqfd1jkGPm3Uy7L11Su-6W8E8jXwGBq_-o_OFt-_FP_Ks3U2pME_bbMYH6w20kzt7cWp_QHyRh9P76ySfwHg_I9A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733603794</pqid></control><display><type>article</type><title>Synthesis and Pharmacological Evaluation of SNC80 Analogues with a Bridged Piperazine Ring</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Holl, Ralph ; Jung, Bettina ; Schepmann, Dirk ; Humpf, Hans-Ulrich ; Grünert, Renate ; Bednarski, Patrick J. ; Englberger, Werner ; Wünsch, Bernhard</creator><creatorcontrib>Holl, Ralph ; Jung, Bettina ; Schepmann, Dirk ; Humpf, Hans-Ulrich ; Grünert, Renate ; Bednarski, Patrick J. ; Englberger, Werner ; Wünsch, Bernhard</creatorcontrib><description>To discover novel δ‐opioid receptor ligands derived from SNC80 (1), a series of 6,8‐diazabicyclo[3.2.2]nonane derivatives bearing two aromatic moieties was prepared, and the affinity toward δ, μ, and κ receptors, as well as σ receptors, was investigated. After removal of the 4‐methoxybenzyl and 2,4‐dimethoxybenzyl protecting groups, the pharmacophoric N,N‐diethylcarbamoylbenzyl residue was attached to the 6,8‐diazabicyclo[3.2.2]nonane framework to yield the designed δ receptor ligands. In a first series of compounds the benzhydryl moiety of SNC80 was dissected, and one phenyl ring was attached to the bicyclic framework. In a second series of δ ligands the complete benzhydryl moiety was introduced into the bicyclic scaffold. The determined δ receptor affinities show that compounds based on an (R)‐glutamate‐derived bicyclic scaffold possess higher δ receptor affinity than their (S)‐glutamate‐derived counterparts. Furthermore, an intact benzhydryl moiety leads to δ receptor ligands that are more potent than compounds with two separated aromatic moieties. Compound 24, with the same spatial arrangement of substituents around the benzhydryl stereocenter as SNC80, shows the highest δ receptor affinity of this series: Ki=24 nM. Whereas the highly potent δ ligands reveal good selectivity against μ and κ receptors, the σ1 and/or σ2 affinities of some compounds are almost in the same range as their δ receptor affinities, such as compound 25 (σ2: Ki=83 nM; δ: Ki=75 nM). In [35S]GTPγS assays the most potent δ ligands 24 and 25 showed almost the same intrinsic activity as the full agonist SNC80, proving the agonistic activity of 24 and 25. The enantiomeric 4‐benzylidene derivatives 15 and ent‐15 showed selective cytotoxicity toward the 5637 (bladder) and A‐427 (small‐cell lung) human tumor cell lines. δ‐Opioid receptor agonists with a bridged piperazine scaffold were designed and synthesized. Whereas compounds with phenyl residues attached to different ring positions (compounds at center) did not show high δ affinity, introduction of the intact benzhydryl moiety at N8 (compounds at right) led to a potent δ agonist (Y=H2, Ki=24 nM).</description><identifier>ISSN: 1860-7179</identifier><identifier>EISSN: 1860-7187</identifier><identifier>DOI: 10.1002/cmdc.200900358</identifier><identifier>PMID: 19827086</identifier><language>eng</language><publisher>Weinheim: WILEY-VCH Verlag</publisher><subject>Benzamides - chemistry ; Benzamides - pharmacology ; bridged piperazines ; Cell Line ; Cell Line, Tumor ; Cell Proliferation - drug effects ; cytotoxicity ; Humans ; Ligands ; medicinal chemistry ; Molecular Structure ; Piperazines - chemistry ; Piperazines - pharmacology ; Protein Binding ; Receptors, Opioid, delta - agonists ; Receptors, Opioid, delta - metabolism ; structure-affinity relationships ; δ receptor agonists</subject><ispartof>ChemMedChem, 2009-12, Vol.4 (12), p.2111-2122</ispartof><rights>Copyright © 2009 WILEY‐VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4078-f28f4900c1b27436122e379a88e8d641d33836766aabbe2c86863f3a2488b0ff3</citedby><cites>FETCH-LOGICAL-c4078-f28f4900c1b27436122e379a88e8d641d33836766aabbe2c86863f3a2488b0ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcmdc.200900358$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcmdc.200900358$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19827086$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Holl, Ralph</creatorcontrib><creatorcontrib>Jung, Bettina</creatorcontrib><creatorcontrib>Schepmann, Dirk</creatorcontrib><creatorcontrib>Humpf, Hans-Ulrich</creatorcontrib><creatorcontrib>Grünert, Renate</creatorcontrib><creatorcontrib>Bednarski, Patrick J.</creatorcontrib><creatorcontrib>Englberger, Werner</creatorcontrib><creatorcontrib>Wünsch, Bernhard</creatorcontrib><title>Synthesis and Pharmacological Evaluation of SNC80 Analogues with a Bridged Piperazine Ring</title><title>ChemMedChem</title><addtitle>ChemMedChem</addtitle><description>To discover novel δ‐opioid receptor ligands derived from SNC80 (1), a series of 6,8‐diazabicyclo[3.2.2]nonane derivatives bearing two aromatic moieties was prepared, and the affinity toward δ, μ, and κ receptors, as well as σ receptors, was investigated. After removal of the 4‐methoxybenzyl and 2,4‐dimethoxybenzyl protecting groups, the pharmacophoric N,N‐diethylcarbamoylbenzyl residue was attached to the 6,8‐diazabicyclo[3.2.2]nonane framework to yield the designed δ receptor ligands. In a first series of compounds the benzhydryl moiety of SNC80 was dissected, and one phenyl ring was attached to the bicyclic framework. In a second series of δ ligands the complete benzhydryl moiety was introduced into the bicyclic scaffold. The determined δ receptor affinities show that compounds based on an (R)‐glutamate‐derived bicyclic scaffold possess higher δ receptor affinity than their (S)‐glutamate‐derived counterparts. Furthermore, an intact benzhydryl moiety leads to δ receptor ligands that are more potent than compounds with two separated aromatic moieties. Compound 24, with the same spatial arrangement of substituents around the benzhydryl stereocenter as SNC80, shows the highest δ receptor affinity of this series: Ki=24 nM. Whereas the highly potent δ ligands reveal good selectivity against μ and κ receptors, the σ1 and/or σ2 affinities of some compounds are almost in the same range as their δ receptor affinities, such as compound 25 (σ2: Ki=83 nM; δ: Ki=75 nM). In [35S]GTPγS assays the most potent δ ligands 24 and 25 showed almost the same intrinsic activity as the full agonist SNC80, proving the agonistic activity of 24 and 25. The enantiomeric 4‐benzylidene derivatives 15 and ent‐15 showed selective cytotoxicity toward the 5637 (bladder) and A‐427 (small‐cell lung) human tumor cell lines. δ‐Opioid receptor agonists with a bridged piperazine scaffold were designed and synthesized. Whereas compounds with phenyl residues attached to different ring positions (compounds at center) did not show high δ affinity, introduction of the intact benzhydryl moiety at N8 (compounds at right) led to a potent δ agonist (Y=H2, Ki=24 nM).</description><subject>Benzamides - chemistry</subject><subject>Benzamides - pharmacology</subject><subject>bridged piperazines</subject><subject>Cell Line</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>cytotoxicity</subject><subject>Humans</subject><subject>Ligands</subject><subject>medicinal chemistry</subject><subject>Molecular Structure</subject><subject>Piperazines - chemistry</subject><subject>Piperazines - pharmacology</subject><subject>Protein Binding</subject><subject>Receptors, Opioid, delta - agonists</subject><subject>Receptors, Opioid, delta - metabolism</subject><subject>structure-affinity relationships</subject><subject>δ receptor agonists</subject><issn>1860-7179</issn><issn>1860-7187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1PGzEQhi1UVCjttcfKt542-Cv27BG2lCJRoIUKiYs16_Umhv1I7U0h_PouShR662lGmud9NHoJ-cjZhDMmDl1buYlgLGdMTmGH7HPQLDMczJvtbvI98i6le8aUAg5vyR7PQRgGep_cXa-6Ye5TSBS7il7NMbbo-qafBYcNPfmDzRKH0He0r-n1RQGMHnU4npc-0ccwzCnS4xiqmR_DYeEjPofO05-hm70nuzU2yX_YzAPy6-vJTfEtO788PSuOzjOnmIGsFlCr8X3HS2GU1FwIL02OAB4qrXglJUhttEYsSy8caNCyligUQMnqWh6Qz2vvIva_x7cG24bkfNNg5_tlskZKzUajGsnJmnSxTyn62i5iaDGuLGf2pU77Uqfd1jkGPm3Uy7L11Su-6W8E8jXwGBq_-o_OFt-_FP_Ks3U2pME_bbMYH6w20kzt7cWp_QHyRh9P76ySfwHg_I9A</recordid><startdate>20091207</startdate><enddate>20091207</enddate><creator>Holl, Ralph</creator><creator>Jung, Bettina</creator><creator>Schepmann, Dirk</creator><creator>Humpf, Hans-Ulrich</creator><creator>Grünert, Renate</creator><creator>Bednarski, Patrick J.</creator><creator>Englberger, Werner</creator><creator>Wünsch, Bernhard</creator><general>WILEY-VCH Verlag</general><general>WILEY‐VCH Verlag</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20091207</creationdate><title>Synthesis and Pharmacological Evaluation of SNC80 Analogues with a Bridged Piperazine Ring</title><author>Holl, Ralph ; Jung, Bettina ; Schepmann, Dirk ; Humpf, Hans-Ulrich ; Grünert, Renate ; Bednarski, Patrick J. ; Englberger, Werner ; Wünsch, Bernhard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4078-f28f4900c1b27436122e379a88e8d641d33836766aabbe2c86863f3a2488b0ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Benzamides - chemistry</topic><topic>Benzamides - pharmacology</topic><topic>bridged piperazines</topic><topic>Cell Line</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>cytotoxicity</topic><topic>Humans</topic><topic>Ligands</topic><topic>medicinal chemistry</topic><topic>Molecular Structure</topic><topic>Piperazines - chemistry</topic><topic>Piperazines - pharmacology</topic><topic>Protein Binding</topic><topic>Receptors, Opioid, delta - agonists</topic><topic>Receptors, Opioid, delta - metabolism</topic><topic>structure-affinity relationships</topic><topic>δ receptor agonists</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holl, Ralph</creatorcontrib><creatorcontrib>Jung, Bettina</creatorcontrib><creatorcontrib>Schepmann, Dirk</creatorcontrib><creatorcontrib>Humpf, Hans-Ulrich</creatorcontrib><creatorcontrib>Grünert, Renate</creatorcontrib><creatorcontrib>Bednarski, Patrick J.</creatorcontrib><creatorcontrib>Englberger, Werner</creatorcontrib><creatorcontrib>Wünsch, Bernhard</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>ChemMedChem</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holl, Ralph</au><au>Jung, Bettina</au><au>Schepmann, Dirk</au><au>Humpf, Hans-Ulrich</au><au>Grünert, Renate</au><au>Bednarski, Patrick J.</au><au>Englberger, Werner</au><au>Wünsch, Bernhard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis and Pharmacological Evaluation of SNC80 Analogues with a Bridged Piperazine Ring</atitle><jtitle>ChemMedChem</jtitle><addtitle>ChemMedChem</addtitle><date>2009-12-07</date><risdate>2009</risdate><volume>4</volume><issue>12</issue><spage>2111</spage><epage>2122</epage><pages>2111-2122</pages><issn>1860-7179</issn><eissn>1860-7187</eissn><abstract>To discover novel δ‐opioid receptor ligands derived from SNC80 (1), a series of 6,8‐diazabicyclo[3.2.2]nonane derivatives bearing two aromatic moieties was prepared, and the affinity toward δ, μ, and κ receptors, as well as σ receptors, was investigated. After removal of the 4‐methoxybenzyl and 2,4‐dimethoxybenzyl protecting groups, the pharmacophoric N,N‐diethylcarbamoylbenzyl residue was attached to the 6,8‐diazabicyclo[3.2.2]nonane framework to yield the designed δ receptor ligands. In a first series of compounds the benzhydryl moiety of SNC80 was dissected, and one phenyl ring was attached to the bicyclic framework. In a second series of δ ligands the complete benzhydryl moiety was introduced into the bicyclic scaffold. The determined δ receptor affinities show that compounds based on an (R)‐glutamate‐derived bicyclic scaffold possess higher δ receptor affinity than their (S)‐glutamate‐derived counterparts. Furthermore, an intact benzhydryl moiety leads to δ receptor ligands that are more potent than compounds with two separated aromatic moieties. Compound 24, with the same spatial arrangement of substituents around the benzhydryl stereocenter as SNC80, shows the highest δ receptor affinity of this series: Ki=24 nM. Whereas the highly potent δ ligands reveal good selectivity against μ and κ receptors, the σ1 and/or σ2 affinities of some compounds are almost in the same range as their δ receptor affinities, such as compound 25 (σ2: Ki=83 nM; δ: Ki=75 nM). In [35S]GTPγS assays the most potent δ ligands 24 and 25 showed almost the same intrinsic activity as the full agonist SNC80, proving the agonistic activity of 24 and 25. The enantiomeric 4‐benzylidene derivatives 15 and ent‐15 showed selective cytotoxicity toward the 5637 (bladder) and A‐427 (small‐cell lung) human tumor cell lines. δ‐Opioid receptor agonists with a bridged piperazine scaffold were designed and synthesized. Whereas compounds with phenyl residues attached to different ring positions (compounds at center) did not show high δ affinity, introduction of the intact benzhydryl moiety at N8 (compounds at right) led to a potent δ agonist (Y=H2, Ki=24 nM).</abstract><cop>Weinheim</cop><pub>WILEY-VCH Verlag</pub><pmid>19827086</pmid><doi>10.1002/cmdc.200900358</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1860-7179
ispartof ChemMedChem, 2009-12, Vol.4 (12), p.2111-2122
issn 1860-7179
1860-7187
language eng
recordid cdi_proquest_miscellaneous_733603794
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Benzamides - chemistry
Benzamides - pharmacology
bridged piperazines
Cell Line
Cell Line, Tumor
Cell Proliferation - drug effects
cytotoxicity
Humans
Ligands
medicinal chemistry
Molecular Structure
Piperazines - chemistry
Piperazines - pharmacology
Protein Binding
Receptors, Opioid, delta - agonists
Receptors, Opioid, delta - metabolism
structure-affinity relationships
δ receptor agonists
title Synthesis and Pharmacological Evaluation of SNC80 Analogues with a Bridged Piperazine Ring
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T22%3A48%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20and%20Pharmacological%20Evaluation%20of%20SNC80%20Analogues%20with%20a%20Bridged%20Piperazine%20Ring&rft.jtitle=ChemMedChem&rft.au=Holl,%20Ralph&rft.date=2009-12-07&rft.volume=4&rft.issue=12&rft.spage=2111&rft.epage=2122&rft.pages=2111-2122&rft.issn=1860-7179&rft.eissn=1860-7187&rft_id=info:doi/10.1002/cmdc.200900358&rft_dat=%3Cproquest_cross%3E733603794%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733603794&rft_id=info:pmid/19827086&rfr_iscdi=true